Black Rock Inc. Gemini Therapeutics, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.01 $17,647 - $27,076	-13,471 Reduced 6.29%	200,554 $330,000
Q2 2022 Aug 12, 2022	SELL	$1.22 - $1.73 $1.33 Million - $1.88 Million	-1,086,179 Reduced 83.54%	214,025 $361,000
Q1 2022 May 12, 2022	BUY	$1.29 - $3.08 $56,541 - $134,999	43,831 Added 3.49%	1,300,204 $1.81 Million
Q4 2021 Feb 10, 2022	BUY	$2.39 - $4.0 $17,317 - $28,984	7,246 Added 0.58%	1,256,373 $3.66 Million
Q3 2021 Nov 09, 2021	SELL	$3.3 - $6.32 $27,947 - $53,524	-8,469 Reduced 0.67%	1,249,127 $5.05 Million
Q2 2021 Aug 11, 2021	BUY	$6.32 - $14.02 $7.95 Million - $17.6 Million	1,257,596 New	1,257,596 $8.14 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.